Vaccines against COVID-19: Priority to mRNA-Based Formulations
As of September 2021, twenty-one anti-COVID-19 vaccines have been approved in the world. Their utilization will expedite an end to the current pandemic. Besides the usual vaccine formats that include inactivated viruses (eight approved vaccines) and protein-based vaccines (four approved vaccines), t...
Main Author: | Steve Pascolo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/10/2716 |
Similar Items
-
Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype
by: Steve Pascolo
Published: (2021-02-01) -
Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants
by: Jianglong Li, et al.
Published: (2022-10-01) -
An Update on mRNA-Based Viral Vaccines
by: Subbiah Jeeva, et al.
Published: (2021-08-01) -
Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque
by: Alireza Naderi Sohi, et al.
Published: (2021-09-01) -
Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao
by: Hoi Man Ng, et al.
Published: (2023-05-01)